Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04204811 · ClinicalTrials.gov registry record · NA

Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy

A NA study of Ovarian Cancer and Fallopian Tube Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
NA
Development phase
22
Enrollment target
1
Study location

NCT04204811 is a NA study of Ovarian Cancer and Fallopian Tube Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 22 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04204811, a NA study of Ovarian Cancer and Fallopian Tube Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
22 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.

Interventions

  • OTHER Prehabilitation

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2019-12-16
Est. Completion 2026-12-16
Phase NA

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT04204811

The ClinicalTrials.gov registry entry for NCT04204811 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which Prehabilitation is the first listed.

NCT04204811 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04204811 about?

NCT04204811 is a clinical study titled "Prehabilitation Care for Women With Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy". The purpose of this study is evaluate whether a prehabilitation program is feasible and useful for women with advanced ovarian cancer receiving chemotherapy in preparation for debulking surgery.

What is the current status of trial NCT04204811?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2019-12-16. Estimated completion is 2026-12-16.

What conditions does trial NCT04204811 study?

This clinical trial studies the following conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Stage IV Ovarian Cancer.

What interventions are being tested in trial NCT04204811?

The interventions under investigation include: Prehabilitation (OTHER).

Who is sponsoring clinical trial NCT04204811?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04204811 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ovarian Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.